Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide · Genvoya

Small molecule · Inhibitor of HIV-1 integrase and HIV-1 reverse transcriptase · developed by Gilead Sciences

Approved FDA, Nov 2015

GILD Developer

1 Registered trials

What is Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide?

Genvoya is a fixed-dose combination of four antiretroviral drugs: elvitegravir (an HIV-1 integrase strand transfer inhibitor), cobicistat (a CYP3A inhibitor that enhances elvitegravir exposure), emtricitabine, and tenofovir alafenamide (both nucleoside analog reverse transcriptase inhibitors).

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Genvoya
Drug type: Small molecule
Targets: HIV-1 integrase, HIV-1 reverse transcriptase, CYP3A (secondary target)
Mechanism: Inhibitor of HIV-1 integrase and HIV-1 reverse transcriptase
Pathways: HIV replication, viral DNA integration
Therapy area: Infectious disease
Developer: Gilead Sciences Inc (GILD)
FDA status: Approved as Genvoya (November 5, 2015), NDA207561 · FDA label

✅ FDA-approved uses

HIV-1 infection

From the indications section of the FDA label (version of Feb 3, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06337032	Phase 4	HIV-1-infection	Recruiting	GILD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HIV-1-infection

More from Gilead Sciences

Axicabtagene Ciloleucel FDA approved Bictegravir FDA approved Brexucabtagene Autoleucel FDA approved Bulevirtide FDA approved Cobicistat FDA approved Emtricitabine And Tenofovir Alafenamide FDA approved Emtricitabine/Tenofovir Disoproxil FDA approved Lenacapavir FDA approved Remdesivir FDA approved Sacituzumab Govitecan FDA approved Seladelpar FDA approved Tenofovir Disoproxil FDA approved

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the GILD page.

Follow GILD, the company behind Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide

See GILD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GILD catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z